Chemotherapy-induced Alopecia Treatment Device Industry Share and...

Chemotherapy-induced Alopecia Treatment Device Industry Share and Specification forecast To 2030

Veröffentlicht 2025-09-02 09:43:56

The global chemotherapy-induced alopecia (CIA) treatment device market size was valued at USD 67.3 million in 2023 and is forecasted to reach USD 174.7 million by 2030, expanding at a robust CAGR of 14.6% from 2024 to 2030. Chemotherapy-induced alopecia refers to hair loss that occurs as a side effect of chemotherapy drugs, which target rapidly dividing cells in the body, including those in hair follicles. To address this, specialized CIA treatment devices most notably scalp cooling systems are used to prevent or minimize hair loss during treatment. These devices work by lowering the scalp’s temperature, which reduces blood flow to hair follicles, thereby decreasing the concentration of chemotherapy drugs that reach them. This cooling effect helps in preserving hair and improving patients’ emotional well-being and quality of life during cancer treatment.

The market is witnessing strong growth due to several interrelated factors. A key driver is the global rise in cancer incidence, which is influenced by aging populations, changing lifestyles, and exposure to multiple risk factors. Lifestyle-related contributors include tobacco use, alcohol consumption, obesity, and poor dietary habits, while environmental factors such as air pollution and occupational exposures further add to cancer risk. As cancer prevalence continues to rise, so does the demand for supportive care therapies, including CIA treatment devices. According to the World Health Organization (WHO) report published in February 2024, the cancer burden is projected to increase dramatically, with over 35 million new cancer cases expected by 2050, representing a 77% rise from the 20 million cases reported in 2022. This surge highlights the growing need for effective supportive care solutions to improve patient experiences during treatment.

Key Market Trends & Insights:

Regional Insights: North America dominated the CIA treatment device market, capturing 52.80% of the revenue share in 2023. The region benefits from advanced healthcare infrastructure, higher adoption of innovative medical devices, favorable reimbursement policies, and strong awareness among both healthcare providers and patients. Asia Pacific is expected to grow at the fastest CAGR during the forecast period, supported by a rapidly growing cancer population, improving healthcare facilities, rising medical tourism, and increasing adoption of advanced oncology treatment solutions.
Product Type Insights: The manual cooling systems segment accounted for the largest revenue share at 52.7% in 2023, as these devices are relatively cost-effective and widely accessible. The automated cooling systems segment is expected to witness the most lucrative growth rate over the coming years, driven by greater ease of use, improved patient comfort, and rising preference for technologically advanced, efficient solutions.
Sales Modality Insights: The rental sales segment dominated the market with a substantial 80.9% revenue share in 2023, largely due to affordability and convenience for patients who require temporary access during chemotherapy treatment. The direct sales segment is projected to grow at a lucrative CAGR, as healthcare providers and cancer centers increasingly invest in long-term ownership of these devices.
Indication Insights: The breast cancer segment led the market with the highest share of 66.93% in 2023, reflecting the high prevalence of breast cancer cases globally and the strong demand for supportive care among female patients. The ovarian cancer segment is anticipated to grow at the fastest CAGR, supported by the growing recognition of scalp cooling as an important supportive therapy for patients undergoing aggressive chemotherapy regimens.
End-use Insights: The hospital segment emerged as the leading end-user, accounting for 44.85% of revenue in 2023, owing to hospitals being the primary centers for chemotherapy treatment and supportive care. The cancer centers segment is expected to register significant growth during the forecast period, driven by the increasing establishment of specialized cancer treatment facilities that integrate scalp cooling devices as part of their comprehensive oncology care offerings.

Order a free sample PDF of the Chemotherapy-induced Alopecia Treatment Device Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

2023 Market Size: USD 67.3 Million
2030 Projected Market Size: USD 174.7 Million
CAGR (2024-2030): 14.6%
North America: Largest market in 2023
Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

The competitive landscape is characterized by the presence of both established market leaders and emerging players. Major companies such as Dignitana, Paxman, Penguin Cold Caps, and Chemotherapy Cold Caps, Inc. dominate the market through their extensive product portfolios, global presence, and partnerships with oncology treatment centers. These companies adopt strategies such as product innovation, strategic collaborations, and expanding distribution networks to strengthen their market position.

Emerging players like Arctic Cold Caps, LLC, Stemtech Medical Devices, and Polar Cold Caps LLC are also gaining traction by focusing on affordability, user-friendly device designs, and niche market penetration. To remain competitive, industry participants are placing emphasis on identifying market opportunities, analyzing emerging technologies, and adapting to changing patient and provider preferences. This approach ensures sustained growth while addressing the increasing demand for patient-centric cancer care solutions.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The chemotherapy-induced alopecia treatment device market is poised for substantial growth, fueled by the rising global cancer burden, greater patient awareness of supportive care options, and advancements in scalp cooling technologies. While North America currently leads in adoption due to its advanced healthcare systems, Asia Pacific is expected to experience the fastest growth driven by increasing cancer incidence and expanding healthcare infrastructure. With strong demand across hospitals, cancer centers, and rental sales models, the market is witnessing active participation from both established companies and emerging players, positioning it as an increasingly vital segment of cancer care.